阿立哌唑联合癸酸氟哌啶醇治疗残留型精神分裂症的临床研究

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Aripiprazole combined with Haloperidol Decanoate in the treatment of residual schizophrenia. Methods A total of 50 patients with residual schizophrenia who were treated in our hospital from January 2019 to January 2020 were included in this study. According to the random number table control method, they were divided into two groups, 25 cases in each group. The control group received Aripiprazole Tablets. The patients in the study group received Aripiprazole Tablets combined with Haloperidol Decanoate injection. The changes of PANSS and TESS were compared before and after treatment in the two groups.Results The positive symptom score,negative symptom score, general psychopharmacology score and total score of the two groups at 2, 4, 6 weeks of treatment were lower than those of the same group before treatment, the differences were statistically significant (P＜0.05); the positive symptom score, negative symptom score, general psychopharmacology score and total score of the study group at 2,4, 6 weeks of treatment were lower than those of the control group at the same time, the differences were statistically significant (P＜0.05); the TESS scores of the two groups increased gradually at 2, 4, 6 weeks of treatment, the differences were statistically significant(P＜0.05); there were no significant differences in TESS scores between the two groups(P＞0.05). Conclusion The combination of Aripiprazole and Haloperidol Decanoate can improve the therapeutic effect of residual schizophrenia, and will not significantly increase adverse reactions, which is worthy of clinical recommendation.

Key words： Residual schizophrenia Aripiprazole Haloperidol Decanoate Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI San-jiang
	TAN Yuan-hua
	JI Ying
	ZHANG Guang-ping
	ZHANG Bo-cheng

Cite this article:

CAI San-jiang,TAN Yuan-hua,JI Ying, et al. Clinical study of Aripiprazole combined with Haloperidol Decanoate in the treatment of residual schizophrenia[J]. 中国当代医药, 2020, 27(28): 68-70.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I28/68

[1]	李丹，徐彩娟，周燕玲，等.残留型精神分裂症患者的社会功能与精神病性症状及认知功能的相关性[J].中国临床心理学杂志，2018，26（2）：333-335，346.
[2]	程平，邱堂威.精神分裂症阴性症状的药物治疗进展[J].医学综述，2019，25（20）：4117-4121.
[3]	阎得胜，闫可域，祁婧，等.老年患者341 例抗精神病用药分析[J].陕西医学杂志，2020，49（3）：337-340.
[4]	刘学.我院48 例难治性精神分裂症患者残留症状及相关影响因素的调查分析[J].数理医药学杂志，2019，32（10）：1445-1447.
[5]	美国精神医学学会（编著），张道龙等（译）.精神障碍诊断与统计手册[M].第5 版.北京：北京大学出版社，2016：26.
[6]	Leucht S，Barabássy A，Laszlovszky I，et al.Linking PANSS negative symptom scores with the Clinical Global Impressions Scale：understanding negative symptom scores in schizophrenia[J].Neuropsychopharmacology，2019，44（9）：1589-1596.
[7]	Beck S，Patsalis T，Busch A，et al.Long-term results of the reverse Total Evolutive Shoulder System （TESS）[J].Arch Orthop Trauma Surg，2019，139（8）：1039-1044.
[8]	刘雨耕，赵睿智，雷荣，等.改良森田疗法治疗残留型精神分裂症患者精神症状的疗效研究[J].世界最新医学信息文摘，2019，19（78）：99-100.
[9]	黄园园，苏小珍，吴逢春，等.精神分裂症患者持续依从性与复发的纵向研究[J].临床医学工程，2019，26（12）：1743-1744.
[10]	郭街仔.三种药物治疗精神分裂症的效果及不良反应观察[J].药品评价，2019，16（22）：7-8.
[11]	赖元南，李苑琴.阿立哌唑与利培酮对门诊精神分裂症患者社会功能的影响分析[J].中国实用医药，2020，15（6）：159-161.
[12]	魏保华.阿立哌唑治疗精神分裂症的临床效果与安全性[J].当代医药论丛，2020，18（1）：113-114.
[13]	梁忠新，秦轶灵，严文琼，等.认知行为治疗联合阿立哌唑对慢性精神分裂症患者自知力的影响[J].中国医药科学，2019，9（23）：286-288，292.
[14]	谭剑.癸酸氟哌啶醇治疗慢性精神分裂症的研究[J].临床医药文献电子杂志，2017，4（97）：19 168-19 169.
[15]	林三妹.齐拉西酮联合癸酸氟哌啶醇注射液治疗阴性症状精神分裂症的临床疗效研究[J].临床合理用药杂志，2016，9（15）：22-23.
[16]	于天凤.癸酸氟哌啶醇注射液与癸氟奋乃静注射液治疗慢性精神分裂症127 例疗效观察[J].中国实用医药，2015，10（34）：117-118.
[17]	胡雨.阿立哌唑合并氨磺必利治疗以阴性症状为主的精神分裂症疗效研究[J].当代临床医刊，2019，32（6）：515-516.
[18]	谭剑，韩志琴，叶文莉.葵酸氟哌啶醇与利培酮治疗精神分裂症的临床疗效比较[J].实用心脑肺血管病杂志，2016，24（S1）：108-109.